Ibio Company Profile (NYSEMKT:IBIO)

About Ibio (NYSEMKT:IBIO)

Ibio logoiBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:IBIO
  • CUSIP: N/A
  • Web: www.ibioinc.com/
Capitalization:
  • Market Cap: $28.87 million
  • Outstanding Shares: 89,118,000
Average Prices:
  • 50 Day Moving Avg: $0.38
  • 200 Day Moving Avg: $0.40
  • 52 Week Range: $0.30 - $0.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.62
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $522,000.00
  • Price / Sales: 55.31
  • Book Value: $0.15 per share
  • Price / Book: 2.23
Profitability:
  • EBIDTA: ($11,520,000.00)
  • Net Margins: -11,905.41%
  • Return on Equity: -184.80%
  • Return on Assets: -41.63%
Misc:
  • Average Volume: 143,160 shs.
  • Beta: 1.84
  • Short Ratio: 4.59
 
Frequently Asked Questions for Ibio (NYSEMKT:IBIO)

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "IBIO."

Who are some of Ibio's key competitors?

Who are Ibio's key executives?

Ibio's management team includes the folowing people:

  • Robert B. Kay, Executive Chairman of the Board, Chief Executive Officer
  • Robert L. Erwin, President
  • James P. Mullaney, Chief Financial Officer
  • Terence Ryan Ph.D., Chief Scientific Officer
  • Glenn J. Chang CPA, Independent Director
  • Arthur Y. Elliott Ph.D., Independent Director
  • Seymour Flug, Independent Director
  • James T. Hill, Independent Director
  • John D. McKey Jr., Independent Director

How do I buy Ibio stock?

Shares of Ibio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ibio's stock price today?

One share of Ibio stock can currently be purchased for approximately $0.32.


MarketBeat Community Rating for Ibio (NYSEMKT IBIO)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ibio (NYSEMKT:IBIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ibio (NYSEMKT:IBIO)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Ibio (NYSEMKT:IBIO)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Ibio (NYSEMKT:IBIO)
Current Year EPS Consensus Estimate: $-0.150 EPS
Next Year EPS Consensus Estimate: $-0.200 EPS

Dividends

Dividend History for Ibio (NYSEMKT:IBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ibio (NYSEMKT:IBIO)
Insider Trades by Quarter for Ibio (NYSEMKT:IBIO)
Insider Trades by Quarter for Ibio (NYSEMKT:IBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/7/2016Eastern Capital LtdMajor ShareholderBuy6,500,000$0.62$4,030,000.00View SEC Filing  
1/25/2016Eastern Capital Ltdmajor shareholderBuy3,500,000$0.62$2,170,000.00View SEC Filing  
9/17/2014Carl DesantisMajor ShareholderSell138,710$0.67$92,935.70View SEC Filing  
2/3/2014Carl DesantisMajor ShareholderSell28,828$0.55$15,855.40View SEC Filing  
1/31/2014Carl DesantisMajor ShareholderSell74,049$0.56$41,467.44View SEC Filing  
1/29/2014Carl DesantisMajor ShareholderSell128,708$0.58$74,650.64View SEC Filing  
8/13/2013Carl DesantisMajor ShareholderSell37,689$0.50$18,844.50View SEC Filing  
8/8/2013Carl DesantisMajor ShareholderSell324,395$0.54$175,173.30View SEC Filing  
8/6/2013Carl DesantisMajor ShareholderSell53,065$0.50$26,532.50View SEC Filing  
8/2/2013Carl DesantisMajor ShareholderSell99,945$0.50$49,972.50View SEC Filing  
7/30/2013Carl DesantisMajor ShareholderSell34,605$0.51$17,648.55View SEC Filing  
7/26/2013Carl DesantisMajor ShareholderSell27,255$0.50$13,627.50View SEC Filing  
7/23/2013Carl DesantisMajor ShareholderSell39,465$0.51$20,127.15View SEC Filing  
7/19/2013Carl DesantisMajor ShareholderBuy1,732,679$0.52$900,993.08View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ibio (NYSEMKT:IBIO)
Latest Headlines for Ibio (NYSEMKT:IBIO)
Source:
DateHeadline
streetinsider.com logoiBio, Inc. (IBIO) Announces US Patent Granted to AzarGen Biotechnologies for Synthetic Promoter Technology - StreetInsider.com
www.streetinsider.com - July 14 at 3:16 AM
finance.yahoo.com logoETFs with exposure to iBio, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 7:42 PM
streetinsider.com logoForm 4 iBio, Inc. For: May 01 Filed by: ERWIN ROBERT L - StreetInsider.com
www.streetinsider.com - June 17 at 11:20 PM
streetinsider.com logoForm 4 iBio, Inc. For: May 01 Filed by: RUSSELL PHILIP K.
www.streetinsider.com - June 16 at 6:41 PM
nasdaq.com logoiBio, Inc. to Present Plant-Made Pharmaceutical Platform at Plant ... - Nasdaq
www.nasdaq.com - June 5 at 5:51 PM
finance.yahoo.com logoETFs with exposure to iBio, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 5:51 PM
finance.yahoo.com logoiBio, Inc. to Present Plant-Made Pharmaceutical Platform at Plant-Based Vaccines, Antibodies & Biologics Conference
finance.yahoo.com - June 5 at 10:26 AM
finance.yahoo.com logoETFs with exposure to iBio, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 9:00 PM
finance.yahoo.com logoiBio, Inc. :IBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 11:37 AM
finance.yahoo.com logoiBio, Inc. Provides Corporate Update at Annual Shareholders Meeting
finance.yahoo.com - May 4 at 5:57 PM
businesswire.com logoGlobal Hereditary Angioedema Market: Size, Trends & Forecasts 2017-2021 Featuring Shire, iBio, Pharming Group & CSL Limited - Research and Markets
www.businesswire.com - April 27 at 11:24 PM
finance.yahoo.com logoETFs with exposure to iBio, Inc. : April 25, 2017
finance.yahoo.com - April 25 at 5:20 PM
finance.yahoo.com logoETFs with exposure to iBio, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:42 PM
reuters.com logoBRIEF-Ibio appoints James Mullaney as CFO
www.reuters.com - March 7 at 11:07 AM
biz.yahoo.com logoIBIO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 5:22 PM
biz.yahoo.com logoIBIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Ma
biz.yahoo.com - February 24 at 7:07 PM
reuters.com logoBRIEF-iBio files for non timely 10-Q - Reuters
www.reuters.com - February 14 at 7:11 PM
prnewswire.com logoAstellas Names Linda Friedman General Counsel for Worldwide Legal Organization and Executive Committee Member - PR Newswire (press release)
www.prnewswire.com - February 8 at 11:30 PM
finance.yahoo.com logoCourt Schedules Hearing To Consider Approval Of Settlement Of Derivative Action
finance.yahoo.com - January 27 at 7:45 PM

Social

This page was last updated on 7/23/2017 by MarketBeat.com Staff